No Data
No Data
Aclaris Therapeutics: FDA Clears IND Application For Phase 1A/1B Clinical Trial Of ATI-052, Bispecific Anti-TSLP/IL-4R Monoclonal Antibody; Co. Expects To Initiate Trial In Q2
Express News | Aclaris Therapeutics Secures U.S. Food and Drug Administration Ind Clearance for ATI-052, Enabling Advancement of Its Novel Bispecific Anti-Tslp/Il-4R Investigational Antibody
Aclaris Therapeutics Assumed With an Overweight at Cantor Fitzgerald
Cantor Fitzgerald Initiates Aclaris Therapeutics(ACRS.US) With Buy Rating
Cantor Fitzgerald Reiterates Overweight on Aclaris Therapeuticsto Overweight
Scotiabank Initiates Coverage On Aclaris Therapeutics With Sector Outperform Rating, Announces Price Target of $15
Growth lover : time to buy